| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.28 | 3e-07 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.19 | 5e-07 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-05 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-05 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-05 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.17 | 4e-05 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.17 | 5e-05 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.19 | 5e-05 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.16 | 6e-05 |